FILAB is an independent laboratory providing analytical services such as chemical analysis, analytical development, and powders characterization.

FILAB has a team of 120 employees working in a 5,200 m² laboratory equipped with high-end analytical technqiues : UPLC-MS/MS, LC-QTOF/MS, LC-DAD, GC/MS, ICP/AES, ICP/MS, Ionic Chromatography, Laser Granulometer (PSD), BET, XRD, DSC, SEM – EDX, FTIR, micro- FTIR, TGA…

FILAB supports the pharmaceutical industry through the following services:

• Impurities testing in raw materials and finished pharmaceutical products: residual solvents according to ICH Q3C, elemental impurities according to ICH Q3D (FILAB is the only lab accredited ISO 17025 by COFRAC)… ,
• Analytical development and validation
• Troubleshooting : particles characterization by SEM-EDX , materials failure analysis, unknown impurities identification by LC-MSMS
• Powder material characterization
• Chemical analysis
• Extractables and Leachables (E&L study)
• Stability studies
• Training
• Analysis services for biopharmaceutical products (mAbs, proteins, peptides, oligonucleotides, etc.)

Why FILAB ?

• Working area and environment inspired by GMP
• Unique Chemical Analysis and Materials characterization laboratory platform
• Independent laboratory with high-end analytical services area of 5,200 m²

Since 15th October 2024, the FILAB laboratory has moved to new and more suitable premises with an optimized surface of almost 5,200 m², a few kilometers from our old location.

This move will allow us to:
– improve the quality of our services by improving reactivity in the processing of our clients’ samples;
– integrate new equipment to strengthen our analytical capacity;
– to expand our offer by developing new analyses;
– increase the number of our accreditations to meet future needs;
– Significantly reduce our carbon footprint with a building designed to respect environmental constraints;
– to ensure a professional and safe working environment for our 120 employees, as well as those who will join us as part of our growth.